Author(s)

Huili Zhao ¹

Affiliation(s)

¹ Hangzhou Tongchuang Medical Laboratory, Hangzhou, Zhejiang, China

Corresponding Author

Huili Zhao

ABSTRACT

This report presents a case of intrahepatic cholangiocarcinoma (ICC) initially manifested by a significant elevation of serum CA199. The patient, a middle-aged male with a history of hypertension, renal disease, and renal transplantation, exhibited no typical clinical symptoms but was found to have a persistently elevated CA199 level during follow-up (from 218.6 U/mL to 4000 U/mL). Early imaging studies showed no obvious signs of tumor, but subsequent MRI revealed a nodule in the left lobe of the liver. Postoperative pathology confirmed moderately differentiated cholangiocarcinoma (pathological stage IA). The CA199 level significantly decreased after surgery and gradually returned to normal. This case suggests that persistent isolated elevation of CA199 may be an important indicator of early cholangiocarcinoma, and malignancy should be highly suspected, especially after excluding false positives. Combining imaging and pathological examinations is crucial for the early detection of cholangiocarcinoma, which can effectively improve patient prognosis.

KEYWORDS

Intrahepatic Cholangiocarcinoma; CA199; Tumor Marker; Early Diagnosis

CITE THIS PAPER

Huili Zhao, A Case of Cholangiocarcinoma with Markedly Elevated Serum CA199 as the Initial Symptom. MEDS Public Health and Preventive Medicine (2025) Vol. 5: 94-99. DOI: http://dx.doi.org/10.23977/phpm.2025.050114.

REFERENCES

[1] Bray F, Laversanne M, Sung H, Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCANestimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA: a cancer journal for clinicians, 2024, 74(3): 229-263.
[2] Rodrigues P M, Olaizola P, Paiva N A, Rodrigues P M, Olaizola P, Paiva N A, et al. Pathogenesis of cholangiocarcinoma[J]. Annual Review of Pathology: Mechanisms of Disease, 2021, 16: 433-463.
[3] Li Y, Yu J, Zhang Y, Li Y, Yu J, Zhang Y, et al. Advances in targeted therapy of cholangiocarcinoma[J]. Annals of Medicine, 2024, 56(1): 2310196.
[4] Zhang Shibao. The value of CT and MRI in the diagnosis of intrahepatic cholangiocarcinoma [J]. Imaging Research and Medical Application, 2022,6(3):98-100. DOI:10.3969/j.issn.2096-3807.2022.03.033.
[5] Lee A J, Chun Y S. Intrahepatic cholangiocarcinoma: the AJCC/UICC 8 th edition updates[J]. Chinese clinical oncology, 2018, 7(5): 52.
[6] Lei Lei, Li Junjie, Wang Qianmei, et al. Construction of an Intelligent Tumor Recognition and Classification Diagnosis Model for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Based on Faster-RCNN from Multimodal MR Images [J]. Clinical Misdiagnosis and Treatment, 2022; 35(1):38-42.
[7] Izquierdo-Sanchez L, Lamarca A, La Casta A, Izquierdo-Sanchez L, Lamarca A, La Casta A, et al. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry[J]. Journal of hepatology, 2022, 76(5): 1109-1121.
[8] Luo G, Jin K, Deng S, Luo G, Jin K, Deng S, et al. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter[J]. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 2021, 1875(2): 188409.
[9] Fahrmann J F, Schmidt C M, Mao X, Fahrmann J F, Schmidt C M, Mao X, et al. Lead-time trajectory of CA19-9 as an anchor marker for pancreatic cancer early detection[J]. Gastroenterology, 2021, 160(4): 1373-1383.
[10] Macias R I R, Banales J M, Sangro B, Macias R I R, Banales J M, Sangro B, et al. The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma[J]. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2018, 1864(4): 1468-1477. 
[11] Lapitz A, Azkargorta M, Milkiewicz P, Lapitz A, Azkargorta M, Milkiewicz P, et al. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma[J]. Journal of hepatology, 2023, 79(1): 93-108.
[12] Izquierdo-Sanchez L, Lamarca A, La Casta A, Izquierdo-Sanchez L, Lamarca A, La Casta A, et al. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry[J]. Journal of hepatology, 2022, 76(5): 1109-1121.
[13] Liu Qiuyan. Study on the diagnostic effect of serum CA199, CEA and TBIL on patients with cholangiocarcinoma [J]. Medical Forum Journal, 2024,41(1):53-56.

Sponsors, Associates, and Links

---

• MEDS Clinical Medicine
  
  
• Journal of Neurobiology and Genetics
  
  
• Medical Imaging and Nuclear Medicine
  
  
• Bacterial Genetics and Ecology
  
  
• Transactions on Cancer
  
  
• Journal of Biophysics and Ecology
  
  
• Journal of Animal Science and Veterinary
  
  
• Academic Journal of Biochemistry and Molecular Biology
  
  
• Transactions on Cell and Developmental Biology
  
  
• Rehabilitation Engineering & Assistive Technology
  
  
• Orthopaedics and Sports Medicine
  
  
• Hematology and Stem Cell
  
  
• Journal of Intelligent Informatics and Biomedical Engineering
  
  
• MEDS Basic Medicine
  
  
• MEDS Stomatology
  
  
• MEDS Chinese Medicine
  
  
• Journal of Enzyme Engineering
  
  
• Advances in Industrial Pharmacy and Pharmaceutical Sciences
  
  
• Bacteriology and Microbiology
  
  
• Advances in Physiology and Pathophysiology
  
  
• Journal of Vision and Ophthalmology
  
  
• Frontiers of Obstetrics and Gynecology
  
  
• Digestive Disease and Diabetes
  
  
• Advances in Immunology and Vaccines
  
  
• Nanomedicine and Drug Delivery
  
  
• Cardiology and Vascular System
  
  
• Pediatrics and Child Health
  
  
• Journal of Reproductive Medicine and Contraception
  
  
• Journal of Respiratory and Lung Disease
  
  
• Journal of Bioinformatics and Biomedicine